SLG
GMAB icon

Stanley-Laman Group’s Genmab GMAB Stock Holding History

Stanley-Laman Group’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-14,045
Closed -$573K – 260
2021
Q2 		$573K Buy
14,045
+11
+0.1% +$424 0.08% 210
2021
Q1 		$461K Buy
+14,034
New +$528K 0.08% 213

Other funds holding GMAB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
1832 Asset Management
1832 Asset Management Toronto, Ontario, Canada $109B AUM 35.56% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Stanley-Laman Group's GMAB Position: Q3 2021 in Review

Stanley-Laman Group sold out of Genmab (GMAB) in Q3 2021, closing a stake of 14,045 shares — an estimated $573K sold.

Stanley-Laman Group first reported a position in GMAB in Q1 2021 and held it in 2 quarters. The position peaked at $573K in Q2 2021. 211 funds tracked by Wall St. Rank hold GMAB as of Q3 2021.

  • Stanley-Laman Group reported no remaining Genmab position as of Q3 2021 after selling out during the quarter.
  • Stanley-Laman Group sold 14,045 Genmab shares in Q3 2021, an estimated $573K.
  • Stanley-Laman Group first reported a position in Genmab in Q1 2021 and held it in 2 quarters.
  • Stanley-Laman Group's Genmab position peaked at $573K in Q2 2021.
  • 211 funds tracked by Wall St. Rank held Genmab as of Q3 2021.

Based on Stanley-Laman Group's 13F filing for Q3 2021, filed 3 Nov 2021.